Clinical calculator summary
ProMark 2015 published-score interpreter
Clinical calculator summary
ProMark 2015 published-score interpreter
A source-locked lookup for an externally generated score from the published final eight-protein FFPE needle-biopsy assay.
Evidence-based context for fast calculator use
- Purpose:
- Identify the applicable 2015 pathology operating point without deriving assay values, commercial-scale conversions, risk percentages, or management advice.
- Population:
- Untreated initial-management, clinically localized N0 M0 prostate adenocarcinoma with diagnostic FFPE needle biopsy and biopsy Gleason 3+3 or 3+4.
- Factors:
- Published 0-1 score scale, Final study-era provenance, Diagnostic FFPE needle biopsy, Biopsy Gleason, Clinical extent and treatment context, Externally assigned study-era risk context
- Reference:
- Blume-Jensen et al. Clin Cancer Res. 2015;21:2591-2600; CMS LCD L36675 v19 is shown only as a separate coverage context.
ProMark Published Biomarker Risk Score Interpreter (2015, 0-1 scale)
Enter the final unrounded score on the published 0-1 research scale; commercial 0-100 values are not converted.
Clinical Context & Background
Strict source lookup on the unchanged published 0-1 score: [0,0.33], (0.33,0.80], or (0.80,1].Reference Data
| Published 2015 score | Source interpretation | Boundary |
|---|---|---|
| 0 to 0.33 | Published favorable-pathology operating point met | Inclusive at 0.33 |
| Above 0.33 to 0.80 | Between the published operating points | No named Intermediate category |
| Above 0.80 to 1 | Published nonfavorable-pathology operating point met | Strictly above 0.80 |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use ProMark Published Biomarker Risk Score Interpreter (2015, 0-1 scale) when interpret an externally generated 0-1 score from the final eight-protein biopsy assay published by Blume-Jensen et al. in 2015.
- Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.
How To Interpret
- Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 to 0.33 through Above 0.80 to 1.
- A boundary result should prompt input verification and clinical review rather than false precision.
What To Do Next
- Confirm biopsy versus prostatectomy setting, PSA timing, grade group, clinical/pathologic stage, imaging, life expectancy, and treatment history.
- Document the inputs, result, timing, and clinical context so the assessment can be reproduced.
Limitations
- Diagnostic, post-prostatectomy, genomic, and recurrence tools must be used only at their intended decision point.
- The result supports clinician judgment and does not independently determine treatment.
Validated Population
patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment
How to apply this result
For a representative case, verify Externally generated published score, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed ProMark cases passed through visible production controls at 0, the exact 0.33 favorable boundary, and 0.800001 nonfavorable transition.
- No unexpected N/A, literal undefined value, stale control, unsupported risk gauge, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/promark-prostate-2026-08-03.json.
: Production browser validation
- Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
- Overall browser status: failed-console. medium: Production emitted minified React error #418 during the route load.
- Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.
Case-level production evidence is retained in validation/browser-production/promark-prostate.json.
: Input workflow simplified and revalidated
- Reduced the public form to result-, branch-, unit-, and applicability-changing inputs; removed or consolidated non-scoring, administrative, and duplicate questions.
- Preserved the verified calculation or report-interpretation logic, thresholds, model version, component logic, and supported result pathways behind strict deterministic adapters.
- Passed the calculator-specific regression audit, adapter-parity and malformed-input checks, the 144-calculator input-quality audit, and the 43-calculator entry-burden audit.
: Full validation
- 171/171 independently expected source, boundary, malformed-input, applicability, subgroup/CMS, wording, trace, UI, registry, report, history, and mirror assertions passed.
- This is implementation verification, not independent clinical validation or patient-specific treatment guidance.
: Calculation/input correction
- Reframed the permanent route as the Blume-Jensen 2015 published 0-1 score interpreter.
- Removed Intermediate Risk, active-surveillance and definitive-treatment directives, coercion, rounding, and commercial-scale conflation.
- Added the exact ten-key immutable contract, source applicability, unsupported-scale status, source-backed endpoints, separate CMS context, UI reset, and deterministic trace.
Included in the current validation report.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Related Tools
Frequently Asked Questions
When should ProMark Published Biomarker Risk Score Interpreter (2015, 0-1 scale) be used?
Use it for patients undergoing prostate cancer diagnostic, pathologic, recurrence, or molecular-risk assessment when all required inputs and the intended clinical setting are confirmed.
Can ProMark Published Biomarker Risk Score Interpreter (2015, 0-1 scale) determine treatment by itself?
No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.
Evidence-based oncology decision support. Verify with clinical guidelines.